Potential of regulatory T-cell-based therapies in the management of severe COVID-19

In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4(+)CD25(+)FoxP3(+) regulatory T-cell-based therapies could be considered for patient management https://bit.ly/3eKqWPo

Detalles Bibliográficos
Autores principales: Stephen-Victor, Emmanuel, Das, Mrinmoy, Karnam, Anupama, Pitard, Bruno, Gautier, Jean-François, Bayry, Jagadeesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331657/
https://www.ncbi.nlm.nih.gov/pubmed/32616599
http://dx.doi.org/10.1183/13993003.02182-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331657/
https://www.ncbi.nlm.nih.gov/pubmed/32616599
http://dx.doi.org/10.1183/13993003.02182-2020

Ejemplares similares